Clinical implications of intratumor heterogeneity: challenges and opportunities

Ramon y Cajal Agüeras, Santiago; Sese Faustino, Marta; Capdevila Castillo, Clàudia; Aasen, Trond; Mattos Arruda, Leticia de; Diaz-Cano, Salvador J.; Hernandez Losa, Javier; Castellví Vives, Josep

dc.contributor	Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author	Ramon y Cajal Agüeras, Santiago
dc.contributor.author	Sese Faustino, Marta
dc.contributor.author	Capdevila Castillo, Clàudia
dc.contributor.author	Aasen, Trond
dc.contributor.author	Mattos Arruda, Leticia de
dc.contributor.author	Diaz-Cano, Salvador J.
dc.contributor.author	Hernandez Losa, Javier
dc.contributor.author	Castellví Vives, Josep
dc.date.accessioned	2021-10-22T05:54:06Z
dc.date.available	2021-10-22T05:54:06Z
dc.date.issued	2020-02
dc.identifier.citation	Ramón y Cajal S, Sesé M, Capdevila C, Aasen T, De Mattos-Arruda L, Diaz-Cano SJ, et al. Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med (Berl). 2020 Feb;98(2):161–177.
dc.identifier.issn	1432-1440
dc.identifier.uri	https://hdl.handle.net/11351/6436
dc.description	Heterogeneïtat intratumoral; Intel·ligència artificial; Teràpies antitumorals
dc.description.sponsorship	SRYC received support from Fondo de Investigaciones Sanitarias (PI14/01320 and PI17/02247), Redes Temáticas de Investigación Cooperativa en Salud (RD12/0036/0057), CIBERONC (CB16/12/00363), and Generalitat de Catalunya (AGAUR, 2017 SGR 1799 and 2014 SGR 1131). TA received support from Instituto de Salud Carlos III (grants PI16/00772 and CPII16/00042), co-financed by the European Regional Development Fund (ERDF).
dc.language.iso	eng
dc.publisher	Springer
dc.relation.ispartofseries	Journal of Molecular Medicine;98(2)
dc.rights	Attribution 4.0 International
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/
dc.source	Scientia
dc.subject	Càncer - Tractament
dc.subject	Generacions alternants
dc.subject.mesh	Genetic Heterogeneity
dc.subject.mesh	Neoplasms
dc.subject.mesh	/therapy
dc.title	Clinical implications of intratumor heterogeneity: challenges and opportunities
dc.type	info:eu-repo/semantics/article
dc.identifier.doi	10.1007/s00109-020-01874-2
dc.subject.decs	heterogeneidad genética
dc.subject.decs	neoplasias
dc.subject.decs	/terapia
dc.relation.publishversion	https://doi.org/10.1007/s00109-020-01874-2
dc.type.version	info:eu-repo/semantics/publishedVersion
dc.audience	Professionals
dc.contributor.organismes	Institut Català de la Salut
dc.contributor.authoraffiliation	[Ramón Y Cajal S] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sesé M, Aasen T] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain. [Capdevila C] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Department of Genetics and Development, Columbia University Medical Center, New York, NY 10032, USA. [De Mattos-Arruda L] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Diaz-Cano SJ] Department of Histopathology, King’s College Hospital and King’s Health Partners, London, UK. [Hernández-Losa J, Castellví J] Grup de Patologia molecular translacional, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Barcelona, Spain
dc.identifier.pmid	31970428
dc.identifier.wos	000508697200001
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/PI14%2F01320
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/PI17%2F02247
dc.relation.projectid	info:eu-repo/grantAgreement/ES/1PN/2008-2011/RD12%2F0036%2F0057
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F12%2F00363
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR1799
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F00772
dc.relation.projectid	info:eu-repo/grantAgreement/ES/PE2013-2016/CPII16%2F00042
dc.rights.accessrights	info:eu-repo/semantics/openAccess